Across TCGA pan-cancer cohorts, TRPV2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRPV2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRPV2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TRPV2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, UCEC, and LIHC are the cancer types where TRPV2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	0.973	0.604	.015	23	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
LIHC	DFS	Median	All	0.094	0.555	.002	12	view →
SARC	DFS	Median	All	0.079	0.591	<.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRPV2 tumor-vs-normal RNA expression · all TRPV2 data types